Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene

被引:32
作者
Flasshove, M [1 ]
Bardenheuer, W [1 ]
Schneider, A [1 ]
Hirsch, G [1 ]
Bach, P [1 ]
Bury, C [1 ]
Moritz, T [1 ]
Seeber, S [1 ]
Opalka, B [1 ]
机构
[1] Univ Essen Gesamthsch, W German Canc Ctr, Dept Internal Med Canc Res, D-45122 Essen, Germany
关键词
retroviral vector; green fluorescent protein; gene therapy; internal promoter;
D O I
10.1007/PL00008487
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although gene transfer with retroviral vectors has already been applied to patients as part of clinical protocols, low expression of transgenes in target cells still remains a problem. Therefore, we compared various retroviral vectors using different promoters and backbones for expression of the enhanced green fluorescent protein (EGFP) reporter gene in fibroblasts and CD34(+) cells. Methods: The N2A retroviral vector was used to test expression from the herpes simplex virus thymidine kinase promoter (vector N2A-TK-EGFP), a human phosphoglycerate kinase promoter (vector N2A-PGK-EGFP), and the SV40 promoter (vector N2A-SV-EGFP). Additional constructs used the spleen focus-forming virus (SFFV) long terminal repeat (LTR) as promoter and expressed EGFP alone (vector SF beta 1-EGFP) or EGFP and a downstream (vector SF beta 1-EGFP-IRES) or upstream (vector SF beta 1-IRES-EGFP) internal ribosomal entry site. Results: For NIH 3T3 cells the fluorescence-activated cell sorting analysis revealed that the most active internal promoter was the SV40 promoter in the vector N2A-SV-EGFP (mean fluorescence intensity, MFI, 66.7 +/- 0.4), followed by N2A-PGK-EGFP (26.3 +/- 1.8 MFI), and N2A-TK-EGFP (4.8 +/- 0.1 MFI). Expression from the SF beta 1-EGFP vector (82.6 +/- 6.7 MFI) and the SF beta 1-EGFP-IRES vector (102.8 +/- 6.2 MFI) was higher than from SF beta 1-IRES-EGFP vector (15.5 +/- 1.8 MFI). In human CD34-positive cells, the EGFP expression from all vectors was considerably lower than in fibroblasts with the SF beta 1-EGFP vector still being four- to fivefold more active than the internal promoters tested. Conclusion: The SFFV LTR seems to allow a high expression of transgenes, as long as the transgene is not expressed downstream of an internal ribosomal entry site. Internal promoters may be useful for targeted gene expression in specific cell types, but the reduced level of expression from some internal promoters has to be taken into consideration.
引用
收藏
页码:391 / 399
页数:9
相关论文
共 43 条
[31]   HUMAN CORD-BLOOD CELLS AS TARGETS FOR GENE-TRANSFER - POTENTIAL USE IN GENETIC THERAPIES OF SEVERE COMBINED IMMUNODEFICIENCY DISEASE [J].
MORITZ, T ;
KELLER, DC ;
WILLIAMS, DA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :529-536
[32]   Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: Evidence of direct viral binding to chymotryptic carboxy-terminal fragments [J].
Moritz, T ;
Dutt, P ;
Xiao, XL ;
Carstanjen, D ;
Vik, T ;
Hanenberg, H ;
Williams, DA .
BLOOD, 1996, 88 (03) :855-862
[33]  
MORITZ T, 1995, CANCER RES, V55, P2608
[34]   PRIMARY STRUCTURE OF THE AEQUOREA-VICTORIA GREEN-FLUORESCENT PROTEIN [J].
PRASHER, DC ;
ECKENRODE, VK ;
WARD, WW ;
PRENDERGAST, FG ;
CORMIER, MJ .
GENE, 1992, 111 (02) :229-233
[35]   Enhanced green fluorescent protein as an efficient reporter gene for retroviral transduction of human multipotent lymphoid precursors [J].
Ramiro, AR ;
De Yébenes, VG ;
Trigueros, C ;
Carrasco, YR ;
Toribio, ML .
HUMAN GENE THERAPY, 1998, 9 (07) :1103-1109
[36]   THE HUMAN-LEUKOCYTE INTEGRIN CD11A PROMOTER DIRECTS EXPRESSION IN LEUKOCYTES OF TRANSGENIC MICE [J].
RITCHIE, KA ;
APRIKIAN, A ;
GOLLAHON, KA ;
HICKSTEIN, DD .
BLOOD, 1995, 86 (01) :147-155
[37]   Cell-surface marking of CD34(+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer [J].
Ruggieri, L ;
Aiuti, A ;
Salomoni, M ;
Zappone, E ;
Ferrari, G ;
Bordignon, C .
HUMAN GENE THERAPY, 1997, 8 (13) :1611-1623
[38]  
SKOTZKO M, 1995, CANCER RES, V55, P5493
[39]   SELECTION OF DRUG-RESISTANT BONE-MARROW CELLS INVIVO AFTER RETROVIRAL TRANSFER OF HUMAN MDR1 [J].
SORRENTINO, BP ;
BRANDT, SJ ;
BODINE, D ;
GOTTESMAN, M ;
PASTAN, I ;
CLINE, A ;
NIENHUIS, AW .
SCIENCE, 1992, 257 (5066) :99-103
[40]  
Sugimoto Y, 1997, CANCER GENE THER, V4, P51